Table 1.
Baseline characteristics.
| Total 1 | DT | Non-DT | ||||
|---|---|---|---|---|---|---|
| n | Median [IQR] No. of pts (valid%) | n | Median [IQR] No. of pts (valid%) | n | Median [IQR] No. of pts (valid%) | |
| At initial diagnosis | ||||||
| Age, yr. | 307 | 65 [59–70] | 115 | 64 [59–70] | 192 | 65 [60–69] |
| iPSA, ng/mL | 299 | 59 [14–276] | 110 | 61 [12–231] | 179 | 59 [16–300] |
| PGG | ||||||
| PGG ≤ 3 | 296 | 107 (36) | 35 | 35 (31) | 184 | 72 (38) |
| PGG 4-5 | 296 | 189 [64] | 77 | 77 [69] | 184 | 112 [58] |
| T-stage | ||||||
| <T3 | 219 | 52 (24) | 87 | 17 (15) | 132 | 35 (27) |
| T3-T4 | 219 | 167 [76] | 87 | 70 [61] | 132 | 97 [73] |
| N-stage | ||||||
| N0 | 243 | 96 (40) | 98 | 42 (43) | 145 | 54 (37) |
| N1 | 243 | 147 [60] | 98 | 56 [57] | 145 | 91 [63] |
| M-stage | ||||||
| M0 | 307 | 120 (39) | 115 | 49 (43) | 192 | 71 (37) |
| M1a | 307 | 19 (6.2) | 115 | 6 (5.2) | 192 | 13 (6.8) |
| M1b | 307 | 87 (28) | 115 | 34 (30) | 192 | 53 (28) |
| M1c | 307 | 81 (26) | 115 | 26 (23) | 192 | 55 (29) |
| Volume status2 | ||||||
| Low | 151 | 57 (38) | 55 | 29 (53) | 96 | 32 (33) |
| High | 151 | 94 (62) | 55 | 26 (47) | 96 | 64 (67) |
| At inclusion | ||||||
| Age, yr. | 307 | 70 [65–74] | 115 | 70 [65–75] | 192 | 71 [65–74] |
| PSA, ng/mL | 285 | 25 [8.0–77] | 105 | 32 [6.4–100] | 180 | 24 [9.3–51] |
| Time from ADT to CRPC | ||||||
| Median, mo. | 307 | 20 [12–35] | 115 | 21 [12–34] | 192 | 20 [12–36] |
| <24 mo. | 307 | 781 (59) | 115 | 71 (62) | 192 | 110 (57) |
| Previous CRPC-treatment | ||||||
| None | 307 | 169 (55) | 115 | 53 (46) | 192 | 116 (60) |
| ARSI | 307 | 107 (35) | 115 | 45 (39) | 192 | 62 (32) |
| Docetaxel | 307 | 17 (5.5) | 115 | 7 (6.1) | 192 | 10 (5.2) |
| Cabazitaxel | 307 | 2 (0.7) | 115 | 1 (0.9) | 192 | 1 (0.5) |
| Other | 307 | 12 (3.9) | 115 | 9 (7.8) | 192 | 3 (1.5) |
| Bone disease | ||||||
| With bone involvement | 307 | 247 (81) | 115 | 92 (80) | 192 | 155 (81) |
| Bone only disease | 307 | 118 [38] | 115 | 36 [31] | 192 | 82 [43] |
| Visceral disease | ||||||
| With liver involvement | 307 | 3 (1.0) | 115 | 2 (1.7) | 192 | 1 (0.5) |
| Non-liver visceral involvement | 307 | 27 (8.8) | 115 | 10 (8.7) | 192 | 17 (8.9) |
| No visceral disease | 307 | 277 (90) | 115 | 103 (90) | 192 | 174 (90) |
| Family history3 | ||||||
| Familial prostate cancer | 305 | 13 (4.3) | 115 | 4 (3.5) | 190 | 9 (4.7) |
| Breast cancer | 305 | 31 [10] | 115 | 10 (8.7) | 190 | 21 [11] |
| Ovarian cancer | 305 | 5 (1.6) | 115 | 3 (2.6) | 190 | 2 (1.1) |
| Pancreatic cancer | 305 | 18 (5.9) | 115 | 9 (7.8) | 190 | 9 (4.7) |
1: The table includes all included participants in which NGS results were generated independent of tumour content, this includes three patients in the GMT group and thirteen in the non-GMT group without a valid NGS. The five patients where NGS analysis was not possible are included in the non-GMT group, since no GMT advice could have been given.
2: Volume status for M1b and M1c assessed according to CHAARTED criteria: ≥ 4 bone metastasis, including ≥ 1 outside vertebral column or pelvis and/or visceral metastasis [51].
3: According to the Dutch Consensus criteria [52].
ADT: androgen deprivation treatment; GMT: genetically matched treatment; iPSA: initial PSA at diagnosis; mo.: months; ARSI: androgen receptor signalling inhibitor, i.e., abiraterone acetate or enzalutamide; other CRPC treatment: either radium-223, combination therapy or therapy within clinical trials; PGG: prognostic grade group; yr.: years.
Percentages below 10% are specified with one decimal place.